Gilead Sciences, Inc.
GILDDrug Manufacturers - General
$170.68+3.06%As of Oct 30vs prior close
- Market cap
- $211.7B
- P/E (TTM)
- –
- Implied growth
- 5.2%
- From 52W high
- 0.00%
- EPS (LTM)
- -$3.15
- Revenue (LTM)
- $31B
- Net margin
- -12.47%
- Dividend yield
- 1.90%
Nomior Score
60
Steady ProfileTop 26% of the scored universe
Growth44
Quality50
Value57
Momentum78
Resilience55
Growth
−0.35%revenue a year over 9 fiscal years
FY16 $30.4BLTM $31B
Connections
Revenue to profitQ3 FY26
29% of revenue became net profit, down 10 pts on a year.
Latest resultsthird quarter 2026
- Diluted EPS
- $1.94
- Adjusted EPS
- $2.55
Product sales rose in the quarter, led by HIV products, Trodelvy and Livdelzi, partly offset by lower Veklury and Cell Therapy sales. Diluted EPS fell mainly on net losses from equity securities, higher operating expenses and higher income tax expense, while non-GAAP EPS rose on higher product sales and lower acquired IPR&D expenses. The company raised its full-year product sales outlook and widened its expected loss per share.
Who owns it
7funds, 3 tracked portfolios